Today’s article highlights two penny stocks that boast “Strong Buy” consensus ratings from the analyst community and massive upside potential: a specialty pharmaceutical company developing patient-friendly injectables for indications in diabetes, epilepsy, and immunology, and a biotech company developing an intravenously delivered immuno-oncolytic virus for the treatment of solid tumors. For these two stocks, CLICK HERE.
2 Biotech/Pharma Penny Stocks With “Strong Buy” Ratings – And Massive Upside Potential
- by Alex Clarke
Tags:Biotech InvestingBiotech StocksConsensus RatingsInvestPharma Penny StocksStock MarketStocksStrong Buy RatingsUpside Potential